Q2 Solutions, Thermo Fisher partner on oncology testing

By LabPulse.com staff writers

June 2, 2020 -- Thermo Fisher Scientific and clinical trial laboratory company Q2 Solutions are partnering on a plan to reduce the turnaround time for laboratory tests necessary for patients in oncology clinical trials.

Through the partnership, Q2 Solutions will use its assays and tests with Thermo Fisher's Ion Torrent Genexus system, a fully integrated next-generation sequencing platform. The goal is to reduce the time to clinical laboratory results, which are often required before patients can undergo experimental treatment in oncology clinical trials.

Thermo Fisher, WuXi, Mayo Clinic to develop COVID-19 test
Thermo Fisher Scientific announced it is working with WuXi Diagnostics and Mayo Clinic to develop a COVID-19 antibody test.
Thermo Fisher bee sting allergy test clears FDA
Thermo Fisher Scientific has received U.S. Food and Drug Administration clearance for its ImmunoCap Specific Immunoglobulin E Stinging Insect Allergen...
Thermo Fisher grows Q1 revenues
Revenues at Thermo Fisher Scientific grew 2% for the first quarter (end-March 31), although the company's net income slipped.
Thermo Fisher teams up with Ford on COVID-19 testing
Thermo Fisher Scientific and Ford Motor Co. are collaborating on the production of collection kits for COVID-19 tests.
Thermo Fisher withdraws 2020 annual guidance
Thermo Fisher Scientific has withdrawn the 2020 annual guidance it released in January due to the COVID-19 pandemic.

Copyright © 2020 LabPulse.com

Last Updated ls 6/2/2020 2:28:42 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email